Related Experiment Videos

Antiplatelet therapy in diabetic ischemic stroke patients: associated factors and outcomes

Y Hassan1, S W Al-Jabi, N Abd Aziz

  • 1Department of Pharmacy Practice, Faculty of Pharmacy, Universiti Teknologi MARA, Malaysia. dryahaya2909@puncakalam.utim.edu.my

International Journal of Clinical Pharmacology and Therapeutics
|October 4, 2011
PubMed

Insights

Antiplatelet therapy is underused in diabetic stroke patients, especially for primary prevention. However, its use is linked to better stroke outcomes, highlighting a need for improved prescription and adherence to guidelines.

Area of Science:

  • Cardiology
  • Neurology
  • Endocrinology

Background:

  • Diabetes mellitus (DM) increases risk of atherosclerotic complications like stroke.
  • Clinical guidelines recommend antiplatelet therapy for stroke prevention in diabetic patients.

Purpose of the Study:

  • Determine prevalence of pre-stroke antiplatelet therapy in diabetic ischemic stroke patients.
  • Identify factors associated with antiplatelet use.
  • Assess the impact of prior antiplatelet therapy on stroke outcomes.

Main Methods:

  • Observational study of 295 diabetic acute ischemic stroke patients in Malaysia.
  • Data collected from medical records including demographics, risk factors, and antiplatelet use.
  • Stroke outcomes assessed using Glasgow Coma Scale and Modified Barthel Index.

Main Results:

  • Prevalence of previous antiplatelet use was 38.3%.
  • Previous stroke and ischemic heart disease were associated with antiplatelet use.
  • Patients on antiplatelet therapy showed better outcomes (minor GCS at admission, higher MBI at discharge).

Conclusions:

  • Antiplatelet therapy is under-prescribed in diabetic stroke patients, particularly for primary prevention.
  • Strategies to increase antiplatelet use and guideline adherence are needed at national and community levels.
Abstract

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...